FDA Brief

Warning letters Drugs

FDA warning letter to

Sato Pharmaceutical Co., Ltd.

High riskIssued May 18Posted May 26Center for Drug Evaluation and Research (CDER)

FDA says Sato Pharmaceutical's sterile OTC drug line had contamination and stability failures.

What happened

FDA inspected Sato Pharmaceutical's Tokyo facility from November 13 to 21, 2025. Investigators found that the sterile OTC filling line was not properly designed, had at least six failed sterile-process simulations between November 2022 and February 2025, and had microbiological and particulate contamination. FDA also found inadequate stability testing and impurity monitoring and that OTC products were released to the U.S. without required testing for Burkholderia cepacia complex bacteria.

What FDA found

  1. The sterile OTC filling line was not properly designed, and at least six sterile-process simulation failures showed the company could not keep contamination out.

    21 CFR 211.113(b)
  2. The stability program did not identify or monitor impurity peaks and omitted key tests, so the company could not show products stayed safe and effective through expiration.

    21 CFR 211.165(b) and 21 CFR 211.166(a)
  3. The company released OTC products to the U.S. without required microbiological testing, including testing for Burkholderia cepacia complex bacteria.

    21 CFR 211.160(b)

What FDA wants

FDA asks for independent risk assessments and corrective-action plans for the aseptic line and stability program, reserve-sample testing and health-hazard evaluations for released batches, and a commitment not to resume sterile production until the plan is discussed with FDA. Sato must reply in writing within 15 working days.

Who should pay attention

  • U.S. importers and distributors of Sato OTC drugs
  • patients with weakened immune systems or chronic lung conditions
  • drugmakers using similar sterile filling lines or stability programs

This is a summary. Read the original letter on fda.gov.

Sato Pharmaceutical Co., Ltd.'s FDA history

Recalls in the last 12 months

Jun 10 Class III Sato Pharmaceutical Inc.
Food
Yunker(branded) Energy & Health Herbal Supplement with Vitamins; Manufactured by Sato Pharmaceuticals Co. Ltd.; 30ml container. Packed in single serving, 3 units/pack, and 10 units per pack. Single UPC: 49873-916-11 3pa…
Product does not meet label claim for Vitamin E.
Feb 4 Class II Sato Pharmaceutical Co., Ltd
Drug
INON ACE Antacid tablets (magnesium aluminosilicate, magnesium hydroxide and simethicone), 75-count bottle, Manufactured by: Sato Pharmaceutical Co., Ltd., NDC 49873-402-01
Failed Disintegration Specifications: above the time expected.

Full company page

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk